Asia Pacific Legionella Testing Market Size, Share & Industry Trends Analysis Report By Type, By End-User (Clinical Laboratories, Hospitals & Clinics, and Others), By Country and Growth Forecast, 2023 - 2030

The Asia Pacific Legionella Testing Market would witness market growth of 10.4% CAGR during the forecast period (2023-2030).

Legionella-causing bacteria are prevalent in various natural and artificial aquatic environments, including water systems in hotels, residences, factories, respiratory therapy equipment, water fountains, misting devices, and spa pools. To stop the proliferation of Legionella in water, health agencies in several nations are constructing effective water safety plans (WSPs). Consequently, there is an increased need for the testing in commercial structures to ensure adherence to regulatory requirements. In addition, recent clinical trials examining treatment and diagnostic approaches for community-acquired pneumonia in adults are a factor in the expansion of the market.

Historically, the diagnostic gold standard for Legionella has been culture-based testing, which can establish connections between human isolates and environmental sources. In several countries within the region, bronchoalveolar lavage (BAL), an invasive procedure utilized for a minority of patients undergoing testing, has traditionally been the principal method of specimen collection for culture testing.

According to the National Library of Medicine, China has experienced the most significant human migration over the last thirty years. From 2000 to 2021, the urbanization rate increased from 36.22% to 64.72%; by 2025, it is projected to have reached 65.5%. The rising industrialization and urbanization in the region are leading to an increasing rate of waterborne diseases. Hence, these factors are driving the market growth in the region.

The China market dominated the Asia Pacific Legionella Testing Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $44,288 Thousand by 2030. The Japan market is registering a CAGR of 9.5% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 11.1% during (2023 - 2030).

Based on Type, the market is segmented into Polymerase Chain Reaction (PCR), Culture Media, Urine Antigen Testing (UAT), Serology, and Direct Fluorescent Antibody (DFA) Test. Based on End-User, the market is segmented into Clinical Laboratories, Hospitals & Clinics, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include QuidelOrtho Corporation, Abbott Laboratories, Merck KGaA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton Dickinson and Company, BioMerieux S.A., IDEXX Laboratories, Inc., Eurofins Scientific SE and Qiagen N.V

Scope of the Study

Market Segments Covered in the Report:

By Type

• Polymerase Chain Reaction (PCR)
• Culture Media
• Urine Antigen Testing (UAT)
• Serology
• Direct Fluorescent Antibody (DFA) Test

By End-User

• Clinical Laboratories
• Hospitals & Clinics
• Others

By Country

• China
• Japan
• India
• South Korea
• Australia
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• QuidelOrtho Corporation
• Abbott Laboratories
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Becton Dickinson and Company
• BioMerieux S.A.
• IDEXX Laboratories, Inc.
• Eurofins Scientific SE
• Qiagen N.V

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free